Treatment of Primary Aldosteronism Increases Plasma Epoxyeicosatrienoic Acids

Abstract

[Figure: see text].

Keywords: aldosterone; eicosanoids; hypertension; insulin resistance; mineralocorticoids.

Figures

Figure 1:. Plasma 14,15- and Total EETs increased after treatment of primary aldosteronism.

Plasma total (▼), 14,15- (●), 11,12- (●), and 8,9 (○)-epoxyeicosatrienoic acid (EET, A) and dihydroxyeicosatrienoic acid (DHET, B) concentrations before (Pre) and three to twelve months after (Post) treatment of primary aldosteronism. Soluble epoxide hydrolase (sEH) activity was estimated indirectly by the molar ratios of individual and total DHET/(EET+DHET) (C). Data for individual EET concentrations appear in Figure S1.

Figure 2:. Plasma aldosterone inversely correlates with EETs in participants with primary aldosteronism.

Correlation between plasma aldosterone and plasma 8,9-EET (A), 11,12-EET (B), 14,15-EET (C), and total EETs (D) concentrations in participants with primary aldosteronism.

Figure 3:. Plasma EETs, DHETs, and ratios in participants receiving aldosterone infusions.

Plasma total (▼), 14,15- (●), 11,12- (●), and 8,9 (○)-epoxyeicosatrienoic acid (EET, A), DHET concentrations (B) and DHET:EET+DHET ratio (C) did not change significantly after 12.5-hour overnight infusion of aldosterone versus vehicle in healthy volunteers.